Investor Relations


Investor Relations

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells.


Corporate Presentation

The following is an investor update, effective January 2023, presented by Robert Bitterman. Mr. Bitterman has been a member of the Board since 2012. He was appointed President and CEO in February of 2023.

Download Phio Corporate Presentation

Market Value
As of
Provided by Refinitiv.